Resources
Explore how healthcare organizations, researchers, and life sciences partners from our global community use TriNetX to turn real-world patient data into evidence that drives progress.
Finally, we outline typical use cases for the RWE-DE where it can broaden the reach of the types of questions that can be addressed by the Sentinel system.
n this cohort study of 1854 patients, the hazard ratio for mortality (0.95) was incongruous with that of the benchmark trial (0.49).
The landscape of clinical trials is evolving, and with it, the approach to site selection. A more patient-centric model is emerging, which flips the traditional process on its head.
Join industry-leading experts as they delve into the latest real-world data (RWD) and real-world evidence (RWE) use cases, highlighting groundbreaking research and publications.
Company recognized with high-level certification for abiding by Spain’s strongest data security measures, sets a new standard for healthcare data protection within its TriNetX LIVE™ platform.
While artificial intelligence (AI) brings significant advancements to clinical trials—including patient recruitment, data analysis, and real-time monitoring—it is not a panacea for the complexities of clinical development.
The global healthcare landscape is rapidly evolving, driven by advancements in technology, changes in regulatory frameworks, and an increased focus on patient-centered care.
Gadi Lachman, President and CEO of TriNetX, discussed the profound impact RWD is having on the healthcare industry in a Crossroads by Alantra podcast episode — Unlocking the Power of Real-World Data — released earlier this month.
“Diversity in clinical trials” is undoubtedly one of the hottest topics in the healthcare industry today and with good reason. Underrepresentation in clinical trials can have significant and wide-ranging consequences
Chronic Lymphocytic Leukemia (CLL), a type of slow-growing cancer of the blood and bone marrow, accounts for 25-30 percent of all leukemia in the Western world and is the most common type of leukemia in adults, with over 100,000 new global incidence cases and over 40,000 death cases reported globally in 2019.
Phenome-Wide Association study (PheWAS) is a powerful tool designed to systematically screen clinical observations derived from medical records (phenotypes) for association with a variable of interest.
To assess the correlation between primary open-angle glaucoma (POAG) and the risk of developing diabetic retinopathy (DR) in patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM).
Upcoming Webinar
From Protocol Draft to Confident Feasibility: Democratizing Study Design with AI
Tuesday, September 15 | 10am ET
Join TriNetX and Parexel to explore how AI and real-world data are transforming clinical feasibility workflows.
Join a global community of innovators. Discover how to turn real-world data into groundbreaking clinical insights.
Meet TriNetX at Events
Bridge the gap between raw data and patient care. Meet the team at flagship healthcare conferences across the globe, and learn how to leverage the TriNetX ecosystem to streamline trial timelines, improve site collaboration, and publish research that changes lives.
Not sure where to start?
Find the right solution for your organization
Take the Real-World Impact Assessment. Answer a few questions to see how TriNetX can drive impact across your clinical and commercial goals.
